Helmerich & Payne shares should be bought on weakness, says BMO Capital After Helmerich & Payne reported lower than expected operating EPS, BMO Capital thinks the subsequent sell-off was overdone. The firm thinks the stock is undervalued, given the company's outsized new build orders and rising international land activity. It keeps an Outperform rating on the stock.
News For HP From The Last 14 Days
Check below for free stories on HP the last two weeks.
Helmerich & Payne upgraded to Neutral from Underperform at Credit Suisse Credit Suisse upgraded Helmerich & Payne to Outperform and raised its price target to $96 from $90 based on valuation and reduced expectations.